O	0	11	Association
O	12	14	of
B-intervention	15	24	tamoxifen
O	25	28	use
O	29	32	and
O	33	40	reduced
O	41	55	cardiovascular
O	56	62	events
O	63	68	among
B-ethinicity	69	74	asian
O	75	82	females
O	83	87	with
O	88	94	breast
O	95	101	cancer
O	101	102	.

O	103	112	Tamoxifen
O	113	115	is
O	116	120	used
O	121	124	for
O	125	131	breast
O	132	138	cancer
O	139	148	treatment
O	149	152	and
O	153	156	has
O	157	161	been
O	162	170	reported
O	171	173	to
O	174	176	be
O	177	187	beneficial
O	188	191	for
O	192	195	the
O	196	210	cardiovascular
O	211	217	system
O	217	218	,
O	219	222	but
O	223	225	it
O	226	228	is
O	229	236	unclear
O	237	244	whether
O	245	254	tamoxifen
O	255	263	exhibits
O	264	265	a
O	266	275	favorable
O	276	290	cardiovascular
O	291	297	effect
O	298	300	in
O	301	306	Asian
O	307	315	patients
O	315	316	.

O	317	321	From
O	322	329	January
O	329	330	,
O	331	335	1998
O	336	338	to
O	339	347	December
O	347	348	,
O	349	353	2006
O	353	354	,
O	355	356	a
O	357	363	breast
O	364	370	cancer
O	371	377	cohort
O	378	383	study
O	384	387	was
O	388	397	conducted
O	398	403	using
O	404	407	the
B-location	408	414	Taiwan
O	415	423	National
O	424	430	Health
O	431	440	Insurance
O	441	449	database
O	449	450	.

O	451	459	Patients
O	460	464	were
O	465	472	divided
O	473	482	according
O	483	485	to
O	486	493	whether
O	494	503	tamoxifen
O	504	507	was
O	508	512	used
O	512	513	.

O	514	519	Study
O	520	529	endpoints
O	530	534	were
B-outcome-Measure	535	545	occurrence
I-outcome-Measure	546	548	of
I-outcome-Measure	549	554	acute
I-outcome-Measure	555	565	myocardial
I-outcome-Measure	566	576	infarction
I-outcome-Measure	577	578	(
I-outcome-Measure	578	581	AMI
I-outcome-Measure	581	582	)
O	582	583	,
B-outcome-Measure	584	592	ischemic
I-outcome-Measure	593	595	or
I-outcome-Measure	596	607	hemorrhagic
I-outcome-Measure	608	614	stroke
O	615	618	and
B-outcome-Measure	619	624	total
I-outcome-Measure	625	639	cardiovascular
I-outcome-Measure	640	646	events
O	646	647	.

O	648	649	A
O	650	655	total
O	656	658	of
B-total-participants	659	660	3
I-total-participants	660	661	,
I-total-participants	661	664	690
O	665	671	female
O	672	680	subjects
O	681	685	were
O	686	694	enrolled
O	695	696	(
O	696	700	mean
O	701	704	age
B-age	705	707	50
I-age	707	708	.
I-age	708	709	1
I-age	709	710	Â±
I-age	710	712	11
I-age	712	713	.
I-age	713	714	3
O	714	715	)
O	715	716	,
B-intervention-participants	717	718	2
I-intervention-participants	718	719	,
I-intervention-participants	719	722	056
O	723	725	of
O	726	730	whom
O	731	739	received
O	740	749	tamoxifen
O	750	753	and
B-control-participants	754	755	1
I-control-participants	755	756	,
I-control-participants	756	759	634
B-control	760	763	did
I-control	764	767	not
O	767	768	.

O	769	775	During
O	776	777	a
O	778	782	mean
O	783	789	follow
O	789	790	-
O	790	792	up
O	793	795	of
O	796	797	6
O	797	798	.
O	798	799	9
O	800	805	years
O	805	806	,
O	807	810	the
O	811	820	tamoxifen
O	821	826	group
O	827	830	had
O	831	832	a
O	833	846	significantly
O	847	852	lower
B-outcome	853	862	incidence
I-outcome	863	865	of
I-outcome	866	869	AMI
O	870	871	(
B-iv-bin-percent	871	872	0
I-iv-bin-percent	872	873	.
I-iv-bin-percent	873	875	15
I-iv-bin-percent	875	876	%
O	877	879	vs
O	879	880	.
B-cv-bin-percent	881	882	0
I-cv-bin-percent	882	883	.
I-cv-bin-percent	883	885	67
I-cv-bin-percent	885	886	%
O	886	887	,
O	888	889	P
O	889	890	=
O	890	891	0
O	891	892	.
O	892	895	008
O	895	896	)
O	896	897	,
B-outcome	898	906	ischemic
I-outcome	907	913	stroke
O	914	915	(
B-iv-bin-percent	915	916	1
I-iv-bin-percent	916	917	.
I-iv-bin-percent	917	919	99
I-iv-bin-percent	919	920	%
O	921	923	vs
O	923	924	.
B-cv-bin-percent	925	926	3
I-cv-bin-percent	926	927	.
I-cv-bin-percent	927	929	30
I-cv-bin-percent	929	930	%
O	930	931	,
O	932	933	P
O	933	934	=
O	934	935	0
O	935	936	.
O	936	939	008
O	939	940	)
O	940	941	,
B-outcome	942	953	hemorrhagic
I-outcome	954	960	stroke
O	961	962	(
B-iv-bin-percent	962	963	0
I-iv-bin-percent	963	964	.
I-iv-bin-percent	964	966	15
I-iv-bin-percent	966	967	%
O	968	970	vs
O	970	971	.
B-cv-bin-percent	972	973	0
I-cv-bin-percent	973	974	.
I-cv-bin-percent	974	976	55
I-cv-bin-percent	976	977	%
O	977	978	,
O	979	980	P
O	980	981	=
O	981	982	0
O	982	983	.
O	983	986	029
O	986	987	)
O	987	988	,
O	989	992	and
B-outcome	993	998	total
I-outcome	999	1013	cardiovascular
I-outcome	1014	1020	events
O	1021	1022	(
B-iv-bin-percent	1022	1023	2
I-iv-bin-percent	1023	1024	.
I-iv-bin-percent	1024	1026	24
I-iv-bin-percent	1026	1027	%
O	1028	1030	vs
O	1030	1031	.
B-cv-bin-percent	1032	1033	4
I-cv-bin-percent	1033	1034	.
I-cv-bin-percent	1034	1036	16
I-cv-bin-percent	1036	1037	%
O	1037	1038	,
O	1039	1040	P
O	1040	1041	<
O	1041	1042	0
O	1042	1043	.
O	1043	1046	001
O	1046	1047	)
O	1048	1052	than
O	1053	1056	the
O	1057	1060	non
O	1060	1061	-
O	1061	1068	exposed
O	1069	1074	group
O	1074	1075	.

O	1076	1081	After
O	1082	1091	adjusting
O	1092	1095	for
O	1096	1109	comorbidities
O	1109	1110	,
O	1111	1120	tamoxifen
O	1121	1124	was
O	1125	1138	independently
O	1139	1149	associated
O	1150	1154	with
O	1155	1156	a
O	1157	1164	reduced
B-outcome	1165	1169	risk
I-outcome	1170	1172	of
I-outcome	1173	1183	myocardial
I-outcome	1184	1194	infarction
O	1195	1196	(
O	1196	1202	hazard
O	1203	1208	ratio
O	1209	1210	[
O	1210	1212	HR
O	1212	1213	]
O	1214	1215	0
O	1215	1216	.
O	1216	1218	22
O	1218	1219	;
O	1220	1222	95
O	1222	1223	%
O	1224	1234	confidence
O	1235	1243	interval
O	1244	1245	[
O	1245	1247	CI
O	1247	1248	]
O	1249	1250	0
O	1250	1251	.
O	1251	1253	07
O	1253	1254	-
O	1254	1255	0
O	1255	1256	.
O	1256	1258	70
O	1258	1259	,
B-outcome	1260	1268	ischemic
I-outcome	1269	1275	stroke
O	1276	1277	(
O	1277	1279	HR
O	1280	1281	0
O	1281	1282	.
O	1282	1284	52
O	1284	1285	;
O	1286	1288	95
O	1288	1289	%
O	1290	1292	CI
O	1293	1294	0
O	1294	1295	.
O	1295	1297	35
O	1297	1298	-
O	1298	1299	0
O	1299	1300	.
O	1300	1302	78
O	1302	1303	)
O	1303	1304	,
B-outcome	1305	1316	hemorrhagic
I-outcome	1317	1323	stroke
O	1324	1325	(
O	1325	1327	HR
O	1328	1329	0
O	1329	1330	.
O	1330	1332	25
O	1332	1333	;
O	1334	1336	95
O	1336	1337	%
O	1338	1340	CI
O	1341	1342	0
O	1342	1343	.
O	1343	1345	07
O	1345	1346	-
O	1346	1347	0
O	1347	1348	.
O	1348	1350	92
O	1350	1351	)
O	1351	1352	,
O	1353	1356	and
B-outcome	1357	1362	total
I-outcome	1363	1377	cardiovascular
I-outcome	1378	1384	events
O	1385	1386	(
O	1386	1388	HR
O	1389	1390	0
O	1390	1391	.
O	1391	1393	54
O	1393	1394	;
O	1395	1397	95
O	1397	1398	%
O	1399	1401	CI
O	1402	1403	0
O	1403	1404	.
O	1404	1406	37
O	1406	1407	-
O	1407	1408	0
O	1408	1409	.
O	1409	1411	78
O	1411	1412	)
O	1412	1413	.

O	1414	1416	In
O	1417	1422	Asian
O	1423	1429	female
O	1430	1436	breast
O	1437	1443	cancer
O	1444	1452	patients
O	1452	1453	,
O	1454	1463	tamoxifen
O	1464	1467	use
O	1468	1471	was
O	1472	1482	associated
O	1483	1487	with
O	1488	1495	reduced
O	1496	1501	risks
O	1502	1504	of
O	1505	1508	AMI
O	1508	1509	,
O	1510	1518	ischemic
O	1518	1519	,
O	1520	1531	hemorrhagic
O	1532	1538	stroke
O	1539	1542	and
O	1543	1548	total
O	1549	1563	cardiovascular
O	1564	1570	events
O	1570	1571	.
